NCT06315634View on ClinicalTrials.gov

Intrathecal Dexmedetomidine vs Midazolame

PHASE4CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

March 15, 2021

Primary Completion Date

March 10, 2022

Study Completion Date

March 10, 2022

Conditions
Postoperative Pain
Interventions
DRUG

Dexmedetomidine

5 micrograms intrathecal dexmedetomidine

DRUG

Midazolam

2 milligrams intrathecal midazolam

DRUG

Bupivacain

12.5 milligrams 0.5% intrathecal hyperbaric bupivacaine

Trial Locations (1)

11796

National cancer institute, Cairo

All Listed Sponsors
lead

National Cancer Institute, Egypt

OTHER

NCT06315634 - Intrathecal Dexmedetomidine vs Midazolame | Biotech Hunter | Biotech Hunter